Tumour Models London Summit 2026
1 December 2026
Hilton London Canary Wharf, London, United Kingdom
The 15th Tumour Models Summit London is described by the organiser as Europe's longest-standing meeting dedicated to advancing preclinical and translational tumour modelling. It brings together drug developers, translational scientists and clinicians from pharma and biotech to discuss human-relevant models, NAMs, AI-enabled approaches, patient-derived systems, biomarkers, tumour microenvironment models and integrated development strategies to improve candidate selection and clinical translation.
33 sessions · 21 speakers
Organiser (1)
Media Partners (4)
Biopharma Asia · STEMCELL Science News · ecancer · Cell and Gene
Sponsors (11)
GemPharmatech · Lide · ChemPartner · Biocytogen · HUB Organoids · Curesponse · WuXi AppTec · HistologiX · Champions Oncology · Certis Oncology · Sygnature Discovery
Speakers (21)
- Lenka Sadilkova Director, Non-Clinical Projects Operations, Eli Lilly & Co.
- John Bridgeman CSO, ImmunoKey
- Adam Robertson Chief Scientific Officer, Hemispherian
- Alaide Morcavallo Senior Scientist, Research, Bioscience & Oncology, AstraZeneca
- Andrew Whale Director - Nonclinical Safety, Immunocore Ltd
- Baldur Sveinbjornsosn Chief Scientific Officer, Lytix Biopharma AS
- Claudio Murgia Unit Head, Target & Disease Biology, Discovery Oncology, Roche
- Frederic Pipp Global Animal Welfare Officer & Director, EMEA & APAC, Merck KGaA
- Himanshu Manchanda Machine Learning Senior Scientist, Bayer
- Martinus Capelle Drug Product Development & Delivery, Distinguished Scientist, Johnson & Johnson
- Moh Tadayyon Co-founder, Apeikon Therapeutics
- Monika Lamba Saini Director, Medical, Translational, & Computational Pathology, GlaxoSmithKline
- Peter King Vice President & Head Of Discovery, Immuneering Corp.
- Phil Jakeman Chief Executive Officer, Matchbio
- Rocio Evangelista Head, Preclinical Pharmacology Medical & Health, Molecular Partners
- Sara Colombetti Senior Leader-Head of Translational Pharmacology, Roche
- Sonja Gill Director, Oncology Safety Combinations, Clinical Pharmacology & Safety Sciences, AstraZeneca
- Alan Barge Chief Executive Officer, 4C Biomed
- Victor Cortes Head, Research, OneChain Immunotherapeutics
- Kuan-Chuan (Eric) Pao Principal Scientist, Co-Founder, Outrun Therapeutics
- Romain Lara Associate Director, AstraZeneca
Agenda
- Chair’s Opening Remarks 2 December 2026
- Evidence – Precision by Design: Accelerating Oncology Drug Discovery with High-Fidelity Models 2 December 2026
- Evidence – Using Translational Models to Overcome Tumour Antigen Heterogeneity & Improve CAR-T Responses in Solid Tumours 2 December 2026
- Insights Exchange – What Drives Confidence in Translational Decision Making? 2 December 2026
- Evidence – Bridging Preclinical Models to Clinical Outcomes Through Integrated Imaging & Biomarker Strategies 2 December 2026
- Evidence – Improving Confidence in Glioblastoma Development by Understanding What Truly Predicts Clinical Success 2 December 2026
- Evidence – Harnessing Liquid Biopsy Signals to Advance Early Cancer Detection, MRD Monitoring, & Predictive Disease Modeling 2 December 2026
- Insights Exchange – How Can We Better Predict Clinical Success Before the Clinic? 2 December 2026
- Evidence – Advancing the 3Rs Through Integrated Use of 3D Spheroids & In Vivo Models in Immuno-Oncology Development 2 December 2026
- Improving Translational Confidence Through Better Designed Animal Models 2 December 2026
- Insights Exchange – How Should Teams Select the Right Model Under Real World Constraints? 2 December 2026
- Inaugural Poster Competition & Afternoon Break 2 December 2026
- Evidence – Understanding Which Models Best Predict Systemic Responses to Intratumoral Immunotherapies 2 December 2026
- Evidence – Using CRISPR Screening to Decode Tumour Microenvironment Biology & Identify Next Generation Immunotherapy Targets 2 December 2026
- Evidence – Exploring the CombiCell Platform to Provides a Clinically Relevant Antigen-Biology Layer for Immunotherapy Discovery 2 December 2026
- Evidence – Engineering More Clinically Relevant Tumour Models to Evaluate Intratumoral Delivery & Turn Cold Tumours Hot 2 December 2026
- Insights Exchange – What Biological Features Are Still Missing From Today’s Tumour Models? 2 December 2026
- Chair’s Closing Remarks 2 December 2026
- Chair’s Opening Remarks 3 December 2026
- Evidence – Leveraging Digital Pathology & AI to Improve Translational Decision-Making in Oncology 3 December 2026
- Evidence – Leveraging Digital Twins & In Silico Clinical Trials to Improve Predictive Modelling and Translational Success 3 December 2026
- Insight Exchange – How Can AI & Computational Models Improve Confidence Before the Clinic? 3 December 2026
- Evidence – Human-Relevant Safety NAMs for Translational Confidence & Therapeutic Index in Oncology Drug Development 3 December 2026
- Evidence – Predicting Safety & Clinical Outcomes Using Preclinical Tumour & Normal Tissue Models with T-Cell Engagers 3 December 2026
- Insight Exchange – Can We Ever Reliably Predict Safety & Efficacy Before the Clinic? 3 December 2026
- Applying Reverse Translation to Improve Predictive Models for Next Generation CAR-T Development 3 December 2026
- Identifying Novel Immunotherapy Targets Using Human-Relevant Tumour Models 3 December 2026
- Panel Discussion: What Evidence Gives Us Confidence That a Model Will Translate? 3 December 2026
- Poster Winner Awarding Ceremony & Afternoon Break 3 December 2026
- Evidence – Building Integrated Development Strategies to Improve Development Time-lines & Reduce Late-Stage Risks 3 December 2026
- Evidence – Moving Beyond Data Generation to Strategic CRO Partnerships in Tumour Model Development 3 December 2026
- Insight Exchange – Building an End-to-End Development Strategy That Delivers Better Decisions 3 December 2026
- Chair’s Closing Remarks 3 December 2026